---
title: "Curadev"
#date: '`r paste("Date:",Sys.Date())`'
fontsize: 12pt
output: html_document
---

<style type="text/css">

body{ /* Normal  */
      font-size: 13px;
  }
}
h1.title {
  font-size: 28px;
  color: DarkBlue;
}
h1 { /* Header 1 */
  font-size: 20px;
  color: DarkBlue;
}
h2 { /* Header 2 */
    font-size: 16px;
  color: DarkBlue;
}

}
code.r{ /* Code block */
    font-size: 12px;
}
pre { /* Code block - determines code spacing between lines */
    font-size: 14px;
}
</style>

\



# **Curadev (competitive strength):  **  
Founded in 2010, a small molecule drug discovery biotech that focuses more on translational research and data-driven program execution. They have swiftly established their credentials by successfully creating and out-licensing their small molecule patents in immune-oncology.



# **Latest news about their STING Program and their partnership: **  
  DECEMBER 2017 - Curadev Announce Research Partnership With University of Texas Southwestern Medical Center, Dallas, TX, USA. The research findings are on the rewiring of tumor cell metabolism. UT Southwestern and Curadev retain a keen interest in translating the research findings into clinically relevant small molecule therapies for their patients.  
  JULY 2017 - *Curadev files provisional patents in its STING program*  


#**Pipeline**  

<img src="timeline_pic.png" style="width:50%; height:70px">
<img src="./company_analysis_excel/curadev.jpg">





For more details, check the reference below.




# Reference   
https://www.curadev.in/index.php  
http://www.prnewswire.co.in/news-releases/curadev-announce-research-partnership-with-university-of-texas-southwestern-medical-center-dallas-tx-usa-662519093.html  
https://www.curadev.in/newsroom-2017.html  



